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Abstract
The recognition of nucleic acids by the innate immune system during viral infection results in the production of type I
interferons and the activation of antiviral immune responses. The RNA helicases RIG-I and MDA-5 recognize distinct types of
cytosolic RNA species and signal through the mitochondrial protein MAVS to stimulate the phosphorylation and activation
of the transcription factors IRF3 and IRF7, thereby inducing type I interferon expression. Alternatively, the activation of NF-
kB leads to proinflammatory cytokine production. The function of MAVS is dependent on both its C-terminal
transmembrane (TM) domain and N-terminal caspase recruitment domain (CARD). The TM domain mediates MAVS
dimerization in response to viral RNA, allowing the CARD to bind to and activate the downstream effector TRAF3. Notably,
dimerization of the MAVS CARD alone is sufficient to activate IRF3, IRF7, and NF-kB. However, TRAF3-deficient cells display
only a partial reduction in interferon production in response to RNA virus infection and are not defective in NF-kB activation.
Here we find that the related ubiquitin ligase TRAF5 is a downstream target of MAVS that mediates both IRF3 and NF-kB
activation. The TM domain of MAVS allows it to dimerize and thereby associate with TRAF5 and induce its ubiquitination in a
CARD-dependent manner. Also, NEMO is recruited to the dimerized MAVS CARD domain in a TRAF3 and TRAF5-dependent
manner. Thus, our findings reveal a possible function for TRAF5 in mediating the activation of IRF3 and NF-kB downstream
of MAVS through the recruitment of NEMO. TRAF5 may be a key molecule in the innate response against viral infection.
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Introduction
The innate immune system is the first line of host defense,
regulating infection directly and signaling to the adaptive immune
system [1,2]. The enhanced production of type I interferons,
including beta interferon (IFN-b), is an early and critical
component of the innate immune host response to virus infection
[3]. Type I interferon production can be stimulated by germ-line
encoded pattern recognition receptors (PRRs) including those
belonging the Toll-like receptor (TLR) and RIG-I-like receptor
(RLR) families [4]. TLRs comprise a family of PRRs that can
recognize pathogen-associated molecular patterns (PAMPs) in-
cluding lipopolysaccharides (LPS), lipoproteins, single-stranded
RNA (ssRNA), double stranded RNA (dsRNA), and unmethylated
CpG-containing DNA. Cytosolic RNAs are recognized by
members of the RLR family including the RIG-I and MDA-5
RNA helicases.
Biochemical and genetic studies suggest that RIG-I and MDA-5
have nonredundant roles as cytoplasmic receptors for different
types of viral RNA-derived PAMPs [5,6,7,8,9]. Different RNA
species are recognized by either RIG-I, MDA-5, or a combination
of both depending on the types of RNA-derived PAMPs that are
displayed. RIG-I has been found to recognize preferentially 59-
triphosphate poly-U/A-rich single-stranded RNA and short
double-stranded (ds) RNA [10,11,12], whereas MDA-5 recognizes
long dsRNA [13]. RNA species that are recognized by RIG-I can
also be derived from the transcriptional products of RNA
polymerase III using AT-rich double-stranded DNA as a template
[14,15]. Preferred RIG-I RNA ligands are able to form a stable
complex with RIG-I and stimulate its ATPase activity, thus
altering its conformation to an ‘‘active’’ signaling form [16,17].
The final ‘‘active’’ form of RIG-I is thought to be one in which the
two N-terminal caspase recruitment domains (CARDs) are
exposed to allow for homodimerization and binding to MAVS.
MAVS function is dependent on both its C-terminal trans-
membrane (TM) domain and its N-terminal caspase recruitment
domain (CARD). The TM domain allows MAVS to insert in the
outer mitochondrial membrane and permits its dimerization in
response to cytosolic RNA. Dimerization of the N-terminal CARD
domain of MAVS allows it to associate with and activate the
downstream signaling molecule and ubiquitin ligase TRAF3.
TRAF3 mediates the activation of the transcription factor IRF3
and IRF7 through an unclear mechanism. However, although
TRAF3 2/2 MEFs display defective innate immunity to virus,
they only reveal a partial defect in IFN-b production and
enhanced activation production of inflammatory cytokines [18].
Thus, other downstream targets for MAVS other than TRAF3
likely exist.
Several other proteins have been implicated to play a role in
RLR signaling downstream of MAVS. Recently a molecule called
MITA/STING has been identified as an important mediator of
type I interferon production by cytosolic nucleic acids [19,20].
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9172While MITA/STING plays a critical role in the cellular response
to many forms of cytosolic DNA, it appears to largely augment
signaling pathways involving RIG-I and MAVS [19,21]. Several
other molecules have also been implicated to play roles as adaptor
proteins downstream of MAVS and TRAF3 including NEMO,
TANK, SINTBAD, and NAP1 [22,23,24]. NEMO is an essential
regulatory subunit of the canonical IkB kinase (IKK) complex and
has been implicated to play a role in both IRF3/7 and NF-kB
activation downstream of MAVS[24]. TANK, SINTBAD, and
NAP1 are related proteins that share a defined TBK1-binding
sequence that can be used to directly bind to TBK1 [22]. Upon
virus infection, TANK has been shown to associate with MAVS as
well as TRAF3 and TBK1 [23]. Also, TANK is able to bridge an
interaction between NEMO and TBK1 [24]. However, how
NEMO might be recruited to the MAVS signaling complex
remains unclear.
Here we have uncovered an important role for TRAF5 in RLR
signaling. We find that the dimerization of MAVS allows it to
associate with TRAF5 and induce its ubiquitination. In addition,
TRAF3 and TRAF5 both mediate the recruitment of NEMO to
the MAVS signaling complex. Whereas TRAF3 mediates IRF3
activation, we find that TRAF5 is important for the activation of
NF-kB as well as IRF3. Our data provide novel insight into how
MAVS functions in antiviral innate immune signaling.
Results
Dimerization of MAVS CARD Is Sufficient to Activate
NF-kB
Previously we found that removal of the MAVS TM domain
impairs the ability of MAVS to dimerize, to activate IRF3/7 and
NF-kB, and to induce IFN-b [25]. Importantly, enforced
dimerization of a MAVS deletion mutant lacking its TM domain
(MAVSDTM) can restore its ability to activate IRF3/7 and induce
IFN-b. These results suggested that the ability of MAVS to
activate IRF3/7 is dependent on its ability to dimerize via the TM
domain. To see whether the ability of MAVS to activate NF-kB
was also reliant on its ability to dimerize, we examined whether
enforced dimerization of MAVSDTM could restore its ability to
activate NF-kB. We tested the ability of a tandem repeat of
MAVSDTM with two copies fused end-to-end (MAVSDTMx2) to
activate NF-kB. In contrast to MAVSDTM, the MAVSDTMx2
fusion can phosphorylate IRF3 and activate IRF3/7 [25].
Similarly, we found that the MAVSDTMx2 fusion, but not
MAVSDTM could elicit NF-kB activation and IkBa phosphory-
lation (Figure 1A and 1B). In addition, we also examined a fusion
of the MAVS CARD to the three tandemly repeated dimerization
domains of FPK (MAVS CARD-FPK3). Proteins attached to FPK
can be induced to dimerize by the addition of the cell-permeable
artificial ligand AP1510 [26]. We previously found that MAVS
CARD-FPK3 could activate IRF3/7 activation and IFN-b
production only in the presence of the dimerizer AP1510. We
also found that this fusion protein could activate NF-kB only in the
presence of dimerizer (Figure 1C). Substitution of a conserved
tryptophan residue for alanine in the CARD domain (W68A), a
mutation that prevents full-length MAVS from inducing IFN-b
and activating IRF3 [25], also prevented MAVS CARD-FPK3
from activating NF-kB (Figure 1C).
Previously, we found using point mutants of MAVS that the
CARD but not the TRAF2/3-interaction motif (TIM) was
important for IRF3/7 and IFN-b induction. We examined
whether NF-kB activation by MAVS was dependent on the
TIM. Introduction of a mutation in the CARD (W68A) but not
the TIM (Q145N) of MAVS impaired its ability to activate NF-kB
and induce IkBa phosphorylation (Figure 1D and 1E). Thus, the
CARD but not the TIM is required for NF-kB activation by
MAVS. These results together suggest that MAVS dimerization is
important for the activation of NF-kB in a CARD-dependent
manner, as previously shown for IRF3/7 [25].
TRAF5 Is an Activator of IRF3 and Interferon Production
Although TRAF3 2/2 MEFs display defective innate
immunity to virus, they reveal only a partial defect in IRF3
activation and IFN-b production [27,28]. Furthermore, these cells
do not exhibit a defect in NF-kB activation, but rather display
enhanced signaling mediated by increased levels of NIK [29].
Given these data and our finding that the MAVS CARD is
required for both IRF3/7 and NF-kB activation, it is likely that
there exists a downstream target for the MAVS CARD other than
TRAF3. We chose to examine the closely related TRAF family
member TRAF5. TRAF5 has been shown to be a potent NF-kB
activator when overexpressed [30] but a possible role in IRF3/7
signaling has yet to be examined. We found that ectopic TRAF5,
but not TRAF3 expression could stimulate IRF3 phosphorylation
and activate an IRF3/7-responsive reporter suggesting that levels
of TRAF5 but not TRAF3 were rate-limiting for signaling to
IRF3/7 (Figures 2A and 2B). The activation of IRF3/7 by TRAF5
was dependent on the N-terminus, which contains a RING finger
and multiple zinc fingers (Figure 2A). TRAF5 overexpression also
activated the Ifnb promoter alone or in synergy with RIG-I,
MAVS, TBK1, or Sendai Virus (SeV) infection (Figures 2C, 2D,
and 2E). Thus, TRAF5 is an upstream activator of IRF3/7 as well
as NF-kB.
TRAF5 Associates with the Dimerized MAVS CARD
We next examined whether TRAF5 may physically and
functionally interact with MAVS. In coimmunoprecipitation
experiments, TRAF5 bound to MAVS (Figure 3A). However,
T R A F 5f a i l e dt ob i n dt oa ni n a c t i v ed e l e t i o nm u t a n to fM A V S
lacking its TM domain (MAVSDTM), demonstrating that the
TM was important for MAVS to bind to TRAF5, as was
previously shown for TRAF3 [25]. TRAF5 binding was restored
when the TM domain of MAVS was replaced with the analogous
domain from Bcl-xL (MAVS-TM) (Figure 3B), a mutant protein
that regains function and binding to TRAF3 also [25,31].
Mutation of the conserved tryptophan residue in the MAVS
C A R D( W 6 8 A )t h a ti se s s e n t i a lf o rf u n c t i o n ,a l s oi m p a i r e d
TRAF5 binding (Figure 3B). Thus, the TM domain and CARD
are both necessary for MAVS to bind to TRAF5. In addition, as
previously shown for TRAF3 [25], we found that TRAF5
associated with MAVS in yeast suggesting a likely direct
interaction (Figure 3D).
We previously found that MAVS could interact with TRAF3
and induce its ubiquitination in a CARD-dependent manner. To
see if TRAF5 ubiquitination might also be enhanced in response
to MAVS activation, we coexpressed TRAF5 with epitope-tagged
Ub, along with a constitutively-active form of RIG-I (RIG-IDRD)
or wild-type MAVS. RIG-IDRD and MAVS both stimulated the
ubiquitination of TRAF5 (Figure 3E). In order to examine
whether TRAF5 ubiquitination could be stimulated by dimeriza-
tion of the MAVS CARD we coexpressed MAVS CARD-FPK3
with TRAF3 or TRAF5. In the presence of dimerizer, the self-
association of the MAVS CARD through FPK3 was able to
induce both TRAF3 and TRAF5 ubiquitination (Figures 3F).
Thus, TRAF5, like TRAF3 is a target of the MAVS CARD
domain after it is dimerized through the TM domain.
To see whether TRAF5 was required for RIG-I and MAVS-
mediated activation of signaling, we knocked down TRAF5
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PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9172Figure1. Dimerization oftheMAVS CARD restores activation of NF-kB. A, C, D HEK293Tcells were transfectedwith wild-type or mutantMAVS,
and an NF-kB reporter, pLuc-PRD(II)2. MAVS CARDmt contains a substitution of alanine for tryptophan at residue 68. Lysates were prepared and
luciferase reporter assay was performed 24 hrs later. AP1510 was added 12 hrs prior to cell lysis (C). In the inset figure in (A), a western blot of lysates for
FLAG-MAVS proteins was performed (A). B, E HEK293T cells were cotransfected with HA-IkBa and pcDNA3 or MAVS proteins and lysates were prepared.
Anti-HA immunoprecipitates were probed for phosphorylated IkBa. Lysates were probed for HA-IkBa and FLAG-tagged MAVS proteins (E).
doi:10.1371/journal.pone.0009172.g001
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and Figure 4A). In luciferase reporter assays, we found that
knockdown of TRAF5 expression impaired both IRF3/7 and NF-
kB activation downstream by RIG-I and MAVS (Figures 3H and
3I). Thus, like TRAF3, TRAF5 appears to function downstream of
MAVS in signal transduction.
Figure 2. TRAF5 activates IRF3 and stimulates interferon-b production. A Luciferase reporter assay was performed in HEK293T cells
cotransfected with FLAG-tagged wild-type or trunctated TRAF3 or TRAF5 expression constructs along with pLuc-PRD(III-I)3. In the inset figure, lysates
were immunoblotted for FLAG-tagged proteins. Luciferase activity was measured 24 hrs following plasmid transfection. B HEK293T cells were
transfected with FLAG-tagged TRAF3 or TRAF5 and HA-IRF3. Lysates were prepared and anti-HA immunoprecipitates were probed for
phosphorylated IRF3 (Ser 396). Lysates were probed for FLAG-TRAF3 and FLAG-TRAF5. C, D, E Luciferase reporter assay was performed in HEK293T
cells cotransfected with expression constructs for the indicated proteins along with pLuc-IFNb. SeV infection was performed six hours following
transfection and 18 hrs prior to luciferase assay (E). Discontinuity in graph indicates a broken Y-axis (C, D).
doi:10.1371/journal.pone.0009172.g002
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PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9172Figure 3. TRAF5 associates with the dimerized MAVS CARD. A, B, C HEK293T cells were cotransfected with FLAG-tagged MAVS constructs
together with HA-tagged TRAF5 and whole cell lysates were prepared. Anti-FLAG immunoprecipitates were probed for HA-TRAF5 or FLAG-MAVS.
Lysates were immunoblotted for HA-TRAF5. D Yeast were transformed with the bait or prey constructs indicated as described in the Materials and
Methods section and streaked onto minimal SD media lacking leucine and tryptophan (SD-LW) or leucine, tryptophan, adenine, and histidine (SD-
LWAH). E HEK293T cells were transfected with FLAG-tagged RIG-I or MAVS constructs, HA-TRAF5, and AU1-Ub. Whole cell lysates were prepared and
anti-HA immunoprecipitates were probed for Ub-conjugated TRAF3 and TRAF5 proteins using AU1 antibody from or total protein using HA antibody.
F HEK293T cells were transfected with FLAG-MAVS CARD-FPK3, HA-TRAF3 or HA-TRAF5, and AU1-Ub. Anti-HA immunoprecipitates were probed for
AU1-Ub conjugates or HA-TRAF3/5. Lysates were immunoblotted for FLAG-MAVS CARD-FPK3. AP1510 was added 12 hrs prior to cell lysis. G, H
HEK293T cells transfected initially with siRNAs targeting GFP or TRAF5. 48 hrs later, cells were transfected with FLAG-RIG-IDRD, FLAG-MAVS, or FLAG-
p65, and pLuc-PRD(III-I)3 (IRF3/7) (G) or pLuc-PRD(II)2 (NF-kB) (H). Luciferase activity was measured 24 hrs following plasmid transfection.
Discontinuity in graph indicates a broken Y-axis (H).
doi:10.1371/journal.pone.0009172.g003
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PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9172Figure 4. TRAF5 is required for IRF3/7 and NF-kB activation in response to RLR signaling. A HEK293T cells were initially transfected with
siRNAs targeting GFP, TRAF3, or TRAF5. 48 hrs later, cells were transfected with pLuc-IFNb and 6 hrs later, poly I:C was transfected. Luciferase activity
was measured 18 hours following poly I:C transfection. In the inset figure, HA-TRAF3 or HA-TRAF5 was cotransfected with siRNAs targeting GFP,
TRAF3, or TRAF5 and anti-HA immunoblots were performed on prepared whole cell lysates. B HEK293T cells were initially transfected with siRNAs
targeting GFP, TRAF3, or TRAF5. 48 hrs later, cells were transfected with HA-IRF3, lysates were prepared, and anti-HA immunoprecipitates were
probed for phosphorylated IRF3 (Ser 396) or total HA-IRF3. Cells were transfected with poly I:C 8 hrs prior to cell lysis. C HEK293T cells were
transfected with siRNAs targeting GFP, TRAF3, or TRAF5. Cell lysates probed for phospho-STAT1 (Y701) or total STAT1. Poly I:C was transfected 8 hrs
prior to cell lysis. D, E Luciferase reporter assays were performed in HEK293T cells transfected with siRNA targeting GFP, MAVS, or TRAF5. 48 hrs
following siRNA transfection, cells were transfected with pLuc-IFN-b, pLuc-PRD(III-I)3 (IRF3/7) or pLuc-PRD(II)2 (NF-kB). SeV infection was performed
4 hrs following transfection and 20 hrs prior to luciferase assay.
doi:10.1371/journal.pone.0009172.g004
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To examine whether TRAF5 in fact plays a role in RLR
signaling, we tested the effect of the knockdown of TRAF5
expression on signaling activated by transfected poly I:C and viral
infection. Knockdown of TRAF5 or TRAF3 by siRNA transfec-
tion diminished Ifnb promoter induction, IRF3 phosphorylation,
and STAT1 phosphorylation in response to transfected poly I:C
(Figures 4A, 4B, 4C). TRAF5 was also required for the full
induction of the Ifnb promoter and activation of IRF3/7 in
response to SeV infection (Figures 4D and 4E). Accordingly,
TRAF5 knockdown inhibited the upregulation of Ifnb and IP-10
mRNAs in response to SeV infection (Figures 5A). IFN-b
production in response to SeV infection was also impaired
(Figure 5B). We also examined the effect of TRAF5 knockdown
on NF-kB activation by RLR signaling. TRAF5 siRNA transfec-
tion inhibited p65/RelA nuclear translocation in response to
transfected poly I:C (Figure 4C). Also knockdown of TRAF5
impaired activation of an NF-kB reporter in response to SeV
infection (Figure 4E). We also found that the induction of Tnfa
mRNA in response to SeV infection was also impaired (Figure 5A).
Therefore, like TRAF3, TRAF5 is necessary for full IRF3/7
activation and IFNb induction in response to RLR signaling,
whereas TRAF5 is also required for NF-kB activation.
In addition to viral RNA, intracellular dsDNA also induces an
innate immune response that promotes IRF3/7 activation. It has
recently been shown that transfected poly dA:dT or infection
several DNA viruses leads to the activation of the RIG-I-MAVS
pathway indirectly via the RNA polymerase-dependent transcrip-
tion of DNA into dsRNA [14,15]. To see if TRAF3 and TRAF5
also mediate this pathway, we examined the activation of IFN-b
production in cells after transfection with poly dA:dT following the
knockdown of TRAF3 or TRAF5 expression. We found that
TRAF3 and TRAF5, like MAVS, were both required for IFN-b
production and the induction of STAT1 phosphorylation in
response to transfected poly dA:dT (Figures 5D and 5E). Thus, the
induction of IFN-b by intracellular B-DNA, like RNA is
dependent on TRAF3 and TRAF5.
Our data together suggest that TRAF3 and TRAF5 each have
at least some nonredundant essential functions in the activation of
IRF3/7 signaling downstream of MAVS. One possibility is that
TRAF3 and TRAF5 can function together in a complex to signal.
To test this possibility we examined whether these two proteins
might be able to associate with one another in a yeast two-hybrid
interaction assay. We were able to detect a TRAF3-TRAF5
interaction in yeast, a result consistent with the possibility that
these two ubiquitin ligases may function as a heterodimeric
complex in RLR signaling (Figure 5F).
NEMO Is Recruited to MAVS in a TRAF3/5-Dependent
Manner
Recently NEMO was identified as an essential adaptor molecule
required for IRF3 and IRF7 activation downstream of MAVS in
RLR signaling pathways [24]. NEMO was previously suggested to
mediate the recruitment of TANK and TBK1 to the MAVS
signaling complex although any physical association with NEMO
and MAVS has yet to be demonstrated. We first examined
whether NEMO could be recruited to the MAVS signaling
complex. We tested if the MAVS CARD, when oligomerized and
activated through FPK3, could coprecipitate NEMO from cells.
We found that NEMO associated with the MAVS CARD-FPK3
fusion when it was oligomerized, but not with the mutant form
(Figure 6A). To check if this interaction was influenced by TRAF3
or TRAF5, we examined the effect of cotransfecting an additional
expression plasmid for TRAF3 or TRAF5. Additional TRAF3 or
TRAF5 expression resulted in an enhancement in the association
of NEMO with MAVS CARD-FPK3 (Figure 6B). Conversely, we
found that association of NEMO with MAVS CARD-FPK3 was
diminished when the expression of TRAF3 or TRAF5 was
knocked down by RNAi (Figure 6C). Thus, TRAF3 and TRAF5
both mediate the recruitment of NEMO to the MAVS signaling
complex.
Discussion
Intracellular RNA is recognized by the RNA helicases RIG-I
and MDA-5 and leads to self-association of MAVS on mitochon-
dria and the activation of pathways leading to IRF3/7 and NF-kB
activation. Previously, we found that dimerization of MAVS
results in its ability to associate with and activate the downstream
molecule TRAF3 [25]. This interaction is dependent on the N-
terminal CARD domain of MAVS. However, genetic disruption
of TRAF3 has been shown to only partially inhibit the response to
virus infection [18,28]. Also TRAF3 has been shown to not be
required for NF-kB activation [18]. Our data in this report find
that the related molecule TRAF5 plays an important role in both
IRF3/7 and NF-kB activation downstream of MAVS. The N-
terminal CARD of MAVS directly associates with and activates
TRAF5. TRAF3 and TRAF5 both appear to be required for the
recruitment of NEMO to the MAVS CARD. In addition to the
response to cytosolic RNA, TRAF3 and TRAF5 also play a role in
production of IFN-b in the response to cytosolic B-DNA.
The identification of TRAF5, in addition to TRAF3, as a
downstream target of MAVS may explain the partial defects in
IRF3 activation and IFN-b induction by RNA virus infection
observed in TRAF3 2/2 MEFs [18,32]. Our results suggest that
TRAF3 and TRAF5 each have at least some nonredundant
functions in IRF3 activation while TRAF5 has an additional role
in NF-kB activation. How TRAF3 and TRAF5 mediate the
recruitment of NEMO remains to be determined. Given the
ability of MAVS to induce the ubiquitination of both TRAF3 and
TRAF5 in a CARD-dependent manner, it is possible that TRAF3
and TRAF5 autoubiquitination may lead to their recognition by
NEMO through its previously characterized two ubiquitin binding
domains, located in the CC2-LZ region and C-terminal zinc finger
[33,34]. In fact, previous studies demonstrated that mutations in
either of these two ubiquitin binding domains in NEMO leads to
an impairment in the activation of type I interferon production by
viral infection or overexpressed MAVS [24,32]. Also, it has been
shown recently that the in vitro ubiquitination of TRAF3 allows it
to bind to NEMO [32]. We propose that autoubiquitination of
TRAF3 and TRAF5 in response to MAVS dimerization leads to
the recruitment of NEMO via its ubiquitin binding domains to the
MAVS signaling complex (see Figure 6).
Previously, TRAF3 knockout cells were found to display a
partial defect in type I interferon production in response to RNA
virus infection, but an enhanced activation of NF-kB activation
and production of inflammatory cytokines as a result of NIK
stabilization. Our results clarify how NF-kB is activated down-
stream of MAVS by identifying TRAF5 as a mediator of the
activation of NF-kB in addition to IRF3. The role of the TRAF
family member TRAF6 has been previously implicated to be
necessary for full NF-kB activation in response to viral infection
and cytosolic RNA [35]. We have found that mutation of the two
TRAF6 binding motifs in MAVS has little effect on its ability to
activate NF-kB (Figure 1D). Also, unlike TRAF3 and TRAF5, we
have been unable to detect binding of TRAF6 to the MAVS
CARD (data not shown). It is possible that full activation of NF-kB
may require both CARD-dependent TRAF5-dependent and
TRAF5 is Regulated by MAVS
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9172Figure 5. TRAF5 is required for the induction of gene expression downstream of RLR signaling. A HEK293T cells were transfected with
siRNAs targeting GFP or TRAF5. 48 hrs later, cells were mock infected or infected with SeV for 8 hrs and total RNA was prepared. Ifnb, IP10, and Tnfa
mRNA levels were measured by real-time RT-PCR using specific primers as described in the Materials and Methods section. GADPH was used as an
internal control. Asterisk, P,0.01 versus GFP siRNA + infection (n=2), double asterisk, P,0.005 versus GFP siRNA + infection (n=2). B, HEK293 cells
were transfected with siRNAs targeting GFP, MAVS, or TRAF5. 48 hrs later, cells were mock infected or infected with SeV. Tissue culture supernatants
were collected 24 hrs following infection and human IFN-b ELISA was performed. The concentration of IFN-b is shown (mean +/- sd). ND, not
detectable. Asterisk, P=0.01 versus GFP siRNA + infection (n=2), double asterisk, P,0.005 versus GFP siRNA + infection (n=2). C, HEK293 cells were
transfected with siRNAs targeting GFP or TRAF5. 48 hrs later, cells were transfected with poly I:C for 2 or 6 hrs or mock treated for 6 hrs. Nuclear
extracts were prepared and analyzed for p65 expression by immunoblotting. TBP was used as a loading control. D, HEK293 cells were transfected
with siRNAs targeting GFP, MAVS, TRAF3, or TRAF5. 48 hrs later, cells were transfected with poly dA:dT or mock treated. Tissue culture supernatants
were collected for human IFN-b ELISA 24 hrs after poly dA:dT transfection. The concentration of IFN-b is shown (mean +/2 sd). ND, not detectable.
Asterisk, P,0.025 versus GFP siRNA + poly dA:dT (n=2), double asterisk, P,0.001 versus GFP siRNA + poly dA:dT (n=2). E, HEK293 cells were
transfected with siRNAs as in (D). 48 hrs later, cells were transfected with poly dA:dT or mock treated for 8 hrs and lysates prepared. Either 1 or 4 ug/
ml of poly dA:dT was used as indicated. Lysates were probed for phospho-STAT1 (Y701) or total STAT1. F, Yeast were transformed with the bait or
prey constructs indicated as described in the Materials and Methods section and streaked onto minimal SD media lacking leucine and tryptophan
(SD-LW) or leucine, tryptophan, adenine, and histidine (SD-LWAH).
doi:10.1371/journal.pone.0009172.g005
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may be differences in the use of signaling molecules between
murine and human cells. Of note, murine and human TRAF6
have been shown to display significant functional differences in the
induction of apoptosis and NF-kB [36]. It remains to be
determined how TRAF5 but not TRAF3 selectively mediates
NF-kB activation downstream of MAVS. While TRAF3 and
TRAF5 may act coordinately to recruit NEMO and TANK to
activate IRF3, TRAF5 alone may recruit NEMO and IKK kinase
subunits to activate NF-kB (Figure 7). It remains to be investigated
how such differential recruitment and/or activation may occur.
Our results reveal a role for TRAF5 in signaling downstream of
MAVS. While TRAF3 and TRAF5 are both important for IRF3/
7 activation and type I interferon production, TRAF5 also plays a
role in NF-kB activation and proinflammatory cytokine induction.
A further understanding of the molecular mechanism of MAVS
signal transduction through TRAF3 and TRAF5 will be important
for the development of novel anti-viral therapeutic approaches.
Materials and Methods
Cell Culture and Transfections
HEK293 and HEK 293T cells were obtained from ATCC. All
cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 50 units penicillin/
ml, and 50 ug streptomycin/ml (Invitrogen). Transient transfec-
tions in HEK293T cells and MEFs were performed using
LipofectAMINE 2000 according to manufacturer’s instructions
(Invitrogen). Poly I:C was transfected at 4 ug/ml with LipofectA-
MINE 2000. For all luciferase assays, cells were cotransfected with
Figure 6. NEMO is recruited to the MAVS CARD in a TRAF3/5-dependent manner. A HEK293T cells were transfected with AU1-NEMO and
FLAG-MAVS CARD-FPK3 or FLAG-MAVS CARDmt-FPK3 where indicated. MAVS CARDmt contains a substitution of alanine for tryptophan at residue
68. Lysates were prepared and anti-FLAG immunoprecipitates were probed for AU1-NEMO. Lysates were probed for FLAG-MAVS-CARD-FPK3 protein
and AU1-NEMO. AP1510 was added to media 12 hrs prior to cell lysis. B HEK293T cells were transfected with AU1-NEMO and FLAG-MAVS CARD-FPK3,
HA-TRAF3 or HA-TRAF5 where indicated. Anti-FLAG-immunoprecipitates were probed for AU1-NEMO. Lysates were immunoblotted for FLAG-MAVS
proteins and AU1-NEMO. AP1510 was added to media 12 hrs prior to cell lysis. C HEK293T cells first transfected with siRNAs targeting GFP, TRAF3, or
TRAF5. 48 hrs later, cells were transfected with FLAG-MAVS CARD-FPK3 and AU1-NEMO. Anti-FLAG-immunoprecipitates were probed for AU1-NEMO.
Lysates were immunoblotted for FLAG-MAVS proteins and AU1-NEMO. AP1510 was added to media 12 hrs prior to cell lysis.
doi:10.1371/journal.pone.0009172.g006
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measured by a dual-luciferase reporter assay system (Promega)
using Renilla luciferase as an internal control. Cells were lysed
and measurements were taken 20–24 hrs following plasmid
transfection.
Reagents
Poly I:C and poly dA:dT was purchased from GE Healthcare
Life Sciences. bbit polyclonal antibody to MAVS was purchased
from Bethyl Laboratories. Mouse monoclonal HA and rabbit
polyclonal HA and AU1 antibodies were from Covance. p65
mouse monoclonal antibody (F-6) was purchased from Santa
Cruz. FLAG M2 antibody was purchased from Sigma. Phos-
phoIRF3 (Ser 396), phosphoIkBa (Ser 32), and phosphoSTAT1
(Tyr 701) rabbit polyclonal antibodies were from Cell Signaling.
Mouse monoclonal antibody recognizing TBP was obtained from
Abcam. AP1510 was obtained from ARIAD and used at 100 nM.
Plasmids
Expression construct for FLAG- and HA-tagged TRAF5 were
constructed by PCR amplification and standard recombinant
DNA techniques. TRAF3DN and TRAF5DN contain N-terminal
deletions of the first 97 from TRAF3 and the first 90 codons from
TRAF5, respectively. The expression construct for HA-IkBa has
been described previously [37]. RIG-IDRD is a C-terminal
deletion mutant of RIG-I containing codons 1 to 734, which has
been previously shown function as a constitutively active mutant
[38]. AU1-tagged NEMO was constructed by ligating the cDNA
fragment from pcDNA3-HA-NEMO [39]into pcDNA3-AU1.
Authenticity of all constructs were confirmed by sequencing
(UCLA sequencing core). Point mutations and deletion mutants
were constructed by PCR mutagenesis (Stratagene). AU1-Ub
expression construct has been described previously [39]. MAVS
EE/DD contains substitutions of aspartic acid for glutamic acid at
codons 155 and 457 located in two consensus TRAF6 binding
motifs [35]. Expression constructs for HA-TRAF3, MAVS WT,
MAVS W68A, MAVS Q145N, MAVSDTM, MAVS-TM,
MAVSDTMx2, MAVS CARD, MAVS-CARD-FPK3, MAVS
CARDmt-FPK3 have been described previously [25]. pLUC-
IFNb, pLUC-PRD(III-I)3, and pLUC-PRD(II)2 have been de-
scribed previously [40].
Immunoblotting and Immunoprecipitations
For all coimmunoprecipitation assays, HEK293T cells were
washed once with phosphate-buffered saline (PBS) (Invitrogen)
and then lysed in EBC150 lysis buffer (50 mM Tris HCl pH 8.0,
150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 0.1 mM
Na3VO4, 1 mM DTT). Lysis buffer was supplemented with
Complete EDTA-free protease inhibitor cocktail (Roche). Ubiqui-
tination of immunoprecipitated TRAF3 and TRAF5 was
performed as described previously [39]. Nuclear extracts were
prepared as described previously [41].
RNA Interference
The target sequences for the siRNAs obtained from Dharmacon




CUAUA; TRAF5#2, GGAUGUAAUGCCAAGGUUA; TANK,
GGAUAGAGAUUCUGCAGUA. For TRAF3 and TRAF5 knock-
down, siRNAs corresponding to TRAF3#1a n dT R A F 5 #1 target
sites were used unless otherwise indicated.
Viral Infections and Nucleic Acid Stimulation
For infections with Sendai virus (Cantell strain; Charles River
laboratories), HEK293T or HEK293 cells were infected for
20 hours at 400 hemagglutinating (HA) units/ml culture media. In
brief, cells seeded on 12 well tissue culture plates were washed
once with PBS, and then incubated with Sendai Virus diluted in
0.5 ml serum-free DMEM. After one hour, 0.5 ml of DMEM
supplemented with 20% fetal bovine serum, 50 units penicillin/ml,
and 50 mg streptomycin/ml was added. For experiments in which
nucleic acid stimulation was performed, either poly I:C or poly
dA:dT (4 ug/ml) was complexed with LipofectAMINE 2000
(4 ul/ml) (Invitrogen) for 15 min prior to addition to media.
Measurement of IFN-b
Human IFN-b ELISA were performed according to the
manufacturers instructions (PBL). 48 hrs following the first siRNA
transfection, cells were infected with SeV and supernatants were
collected 24 hrs later.
RT-PCR
Total RNA was isolated with Trizol reagent (Invitrogen) and
cDNA was reverse-transcribed with oligo-dT primer using
SuperScript III reverse transcriptase (Invitrogen) according to
the manufacturer’s instructions. Real-time PCR analysis was
performed using the iQ SYBR Green Supermix (BioRad) on an
Figure 7. Schematic representation of model for signal
transduction downstream of MAVS. MAVS homodimers, induced
by binding of the activated forms of the RLRs RIG-I and MDA-5, are able
to signal downstream in a TRAF3 and TRAF5-dependent manner to
activate IRF3/7 and in a TRAF5-dependent manner to activate NF-kB.
NEMO may be recruited to the MAVS signaling complex by
ubiquitinated TRAF3 and TRAF5, and may lead to IRF3 phosphorylation
through the recruitment of TANK and TBK1. Alternatively, NEMO may
be recruited to a distinct MAVS signaling complex by ubiquitinated
TRAF5, thereby promoting the recruitment IKKa and IKKb, and leading
to NF-kB activation. The mechanisms underlying the selective
recruitment of signaling molecules to the MAVS signaling apparatus
remain to be determined.
doi:10.1371/journal.pone.0009172.g007
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performed with the following primers: Ifnb,5 9- CAGCAATTTT-
CAGTGTCAGAAGCT-39 and 59-TCATCCTGTCCTTGAG-
GCAGTAT-39; IP10,5 9-TGACTCTAAGTGGCATTCAAGG-
39 and 59-GATTCAGACATCTCTTCTCACCC-39; Tnfa,5 9-
CAGAGGGAAGAGTCCCCCAGGGACC-39 and 59-CCTTG-
GTCTGGTAGGAGACGGCGATG-39; GADPH,5 9- CTGGG-
CTACACTGAGCACCAG-39 and 59- CCAGCGTCAAAGG-
TGGAG-39.
RNA Interference
HEK293 and HEK293T cells were transfected with 100 nM
21mer siRNA oligonucleotide using LipofectAMINE 2000
(Invitrogen) according to manufacturer’s instructions. 24 hrs later,
cells were transfected once more. Viral infections, plasmid and
poly I:C transfections were performed the next day.
Yeast Two-Hybrid Interactions
MAVS, TRAF3, and TRAF5 cDNAs were cloned into the
pGBKT7 bait and pGADT7 prey vectors (Clontech). Constructs
were transformed into AH109 yeast (Clontech) by the lithium
acetate method and multiple colonies grown on minimal media
lacking leucine and tryptophan were streaked out onto minimal
media lacking leucine and tryptophan or leucine, tryptophan,
adenine, and histidine (Clontech). Plates were incubated at 30uC
overnight until colonies formed.
Statistical Analysis
Statistical significance of any differences in mRNA levels or
cytokine concentration was determined by Student’s one-sided t-
test.
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